Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 10,125 Shares

Posted by Brenda Bartman on Aug 12th, 2026

Immunome, Inc. (NASDAQ:IMNM – Get Free Report) Director Isaac Barchas sold 10,125 shares of Immunome stock in a transaction on Monday, August 10th. The shares were sold at an average price of $26.07, for a total value of $263,958.75. Following the transaction, the director owned 62,291 shares in the company, valued at approximately $1,623,926.37. This trade represents a 13.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

On Wednesday, August 12th, Isaac Barchas sold 11,048 shares of Immunome stock. The stock was sold at an average price of $27.25, for a total value of $301,058.00.
On Tuesday, August 11th, Isaac Barchas sold 62,291 shares of Immunome stock. The shares were sold at an average price of $26.23, for a total transaction of $1,633,892.93.
On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total transaction of $397,362.88.
On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total value of $543,090.40.
On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The stock was sold at an average price of $24.20, for a total value of $409,125.20.
On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The shares were sold at an average price of $24.11, for a total value of $2,003,396.34.
On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total value of $2,259,000.00.
On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The shares were sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Trading Up 6.6%

Shares of IMNM traded up $1.74 during midday trading on Wednesday, hitting $27.99. The stock had a trading volume of 1,561,300 shares, compared to its average volume of 1,383,354. Immunome, Inc. has a fifty-two week low of $8.66 and a fifty-two week high of $28.04. The business has a 50-day simple moving average of $21.73 and a two-hundred day simple moving average of $22.18. The firm has a market cap of $3.17 billion, a P/E ratio of -11.76 and a beta of 2.07.

Immunome (NASDAQ:IMNM – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). On average, analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunome

Institutional investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. increased its holdings in Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after buying an additional 5,003,824 shares during the last quarter. BlackRock Inc. acquired a new stake in Immunome in the second quarter valued at approximately $186,588,000. Vanguard Group Inc. lifted its stake in Immunome by 23.4% in the fourth quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after acquiring an additional 1,144,788 shares during the last quarter. Primecap Management Co. CA grew its position in Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after acquiring an additional 1,667,432 shares in the last quarter. Finally, State Street Corp grew its position in Immunome by 37.9% in the fourth quarter. State Street Corp now owns 3,868,000 shares of the company’s stock worth $83,085,000 after acquiring an additional 1,064,027 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Citigroup reissued a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. HC Wainwright restated a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Finally, Wedbush increased their price target on shares of Immunome from $31.00 to $35.00 and gave the stock an “outperform” rating in a research report on Wednesday. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $34.64.

View Our Latest Research Report on IMNM

Trending Headlines about Immunome

Here are the key news stories impacting Immunome this week:

Positive Sentiment: Truist raised its price target to $38 from $37 and maintained a “Buy” rating, implying substantial additional upside from recent levels. The upgraded outlook likely provided the strongest near-term support for Immunome (IMNM). Benzinga analyst price target update
Positive Sentiment: Immunome reported its second-quarter 2026 results and provided a business update. Investors are likely focused on progress in the company’s clinical-stage antibody programs and its development pipeline, which remain key drivers of the stock’s valuation. Immunome second-quarter 2026 results and business update
Neutral Sentiment: Director Isaac Barchas sold a combined 98,712 shares from August 10 through August 12 for approximately $2.6 million. The sales reduced his direct ownership to 92,211 shares, but each transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which may make the activity less indicative of a change in his outlook. The transactions were disclosed in SEC filings. Immunome director insider sales SEC filing
Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, missing the consensus estimate of a $0.51 loss. The larger-than-expected loss underscores the company’s ongoing cash-burn and execution risks typical of a clinical-stage biotechnology company. Immunome quarterly earnings release

Immunome Company Profile

(Get Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.